

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/807,663	07/02/2001	Antonio A. Garcia	A32011-A-PCT 2220			
21003 7.	590 08/13/2002					
BAKER & BO	OTTS	EXAMINER				
30 ROCKEFEI NEW YORK, I			TRAN, MY	TRAN, MY CHAU T		
			ART UNIT	PAPER NUMBER		
			1641 DATE MAILED: 08/13/2002			

Please find below and/or attached an Office communication concerning this application or proceeding.

`		Application	n No.	Applicant(s)			
		09/807,663	3	GARCIA ET AL.			
	Office Action Summary	Examiner		Art Unit			
		My-Chau T	. Tran	1641			
The MAILING DATE of this communication appears on the c ver sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status		ll. 2004					
1)⊠	Responsive to communication(s) filed on <u>06 J</u>		E l				
2a)□	,	is action is r					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4)⊠ Claim(s) <u>1-23</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.						
,	Claim(s) is/are rejected.						
-	Claim(s) is/are objected to.						
•	Claim(s) <u>1-23</u> are subject to restriction and/or e	election real	irement				
•	on Papers	3,000,011,10 <b>q</b> 1					
9)[	The specification is objected to by the Examiner	r.					
10)	Fhe drawing(s) filed on is/are: a)☐ accep	oted or b) 🔲 o	objected to by the Exan	niner.			
	Applicant may not request that any objection to the	-					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
•	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)			(PTO-413) Paper No(s atent Application (PTO			



Application/Control Number: 09/807,663

Art Unit: 1641

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, drawn to a bioassay plate.

Group II, claim(s) 5-15, drawn to a multiwell bioassay plate.

Group III, claim(s) 16, drawn to a method for detecting a first antibody.

Group IV, claim(s) 17-19, drawn to a kit for the detection of a first antibody.

Group V, claim(s) 20-22, drawn to a kit for the detection an antigen.

Group VI, claim(s) 23, drawn to an apparatus for activating microplates.

2. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, pursuant to 37 CFR 1.475(d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group II) comprises the first recited product, (a multiwell bioassay plate). Further pursuant to 37 CFR 1.475(d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

The special technical feature of Group I is considered to be a bioassay plate.

The special technical feature of Group II is considered to be functionalizing a multiwell bioassay plate.

The special technical feature of Group III is considered to be detecting the presence of the first antibody.



Application/Control Number: 09/807,663

Art Unit: 1641

The special technical feature of Group IV is considered to be a kit for the detection of a first antibody.

The special technical feature of Group V is considered to be a kit for the detection an antigen.

The special technical feature of Group VI is considered to be a reagent addition/withdrawal chamber.

Since the technical feature of Group I is not present in Groups II-VI claims and the technical feature of Groups II-VI inventions is not present in Group I claims, unity of invention is lacking. Since the technical feature of Group II is not present in Groups III-VI claims and the technical feature of Groups III-VI inventions is not present in Group II claims, unity of invention is lacking. Since the technical feature of Group III is not present in Groups IV-VI claims and the technical feature of Groups IV-VI invention is not present in Group III claims, unity of invention is lacking. Since the technical feature of Group IV is not present in Group V-VI claims and the technical feature of Groups V-VI invention is not present in Group IV claims, unity of invention is lacking. Since the technical feature of Group V is not present in Group VI claims and the technical feature of Group VI invention is not present in Group V claims, unity of invention is lacking.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to My-Chau T. Tran whose telephone number is 703-305-6999. The examiner can normally be reached on M-F 8:00-4:30.



Application/Control Number: 09/807,663

Art Unit: 1641

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on 703-305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

mct August 3, 2002 BAO-THUY L. NGUYEN PBIMARY EXAMINER